Cancer news source

Filters close
access_time Embargo lifts in 2 days
Embargo will expire: 16-Sep-2024 5:00 PM EDT Released to reporters: 10-Sep-2024 2:00 PM EDT

A reporter's PressPass is required to access this story until the embargo expires on 16-Sep-2024 5:00 PM EDT The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Released: 16-Sep-2024 2:05 PM EDT
Estudo da Mayo Clinic descobre glóbulos brancos disfuncionais ligados ao aumento do risco de melanoma
Mayo Clinic

Pessoas com uma superabundância de glóbulos brancos clonados, ou linfócitos, que prejudicam o seu sistema imunológico — uma condição chamada linfocitose monoclonal de células B (LMB) — podem apresentar um risco elevado de desenvolver várias complicações de saúde, incluindo o melanoma, uma forma de câncer de pele.

Released: 16-Sep-2024 1:05 PM EDT
New Tumor Models Provide Insights Into Deadly Sarcomas
UC Davis Health

Researchers at UC Davis and UCLA have created models for four sarcoma subtypes using stem cells. The findings may lead to new therapies.

Released: 16-Sep-2024 12:05 PM EDT
Estudio De Mayo Clinic Encuentra GlóBulos Blancos Disfuncionales Relacionados Con Un Mayor Riesgo De Melanoma
Mayo Clinic

Personas con una sobreabundancia de glóbulos blancos clonados, o linfocitos, que dañan su sistema inmunológico, una afección llamada linfocitosis monoclonal de células B (LMB), pueden tener un riesgo elevado de desarrollar diversas complicaciones de salud, incluido el melanoma, una forma de cáncer de piel.

Newswise: Arkansas Teacher Earns Master’s Degree to Inspire Son Battling Brain Cancer
Released: 16-Sep-2024 10:05 AM EDT
Arkansas Teacher Earns Master’s Degree to Inspire Son Battling Brain Cancer
University of Arkansas at Little Rock

Heather High, a second-grade teacher and mother of four from Bella Vista, Arkansas, and her 14-year-old son Elijah have something in common – a love of gifted and talented education. High has completed a Master of Education degree in Gifted, Creative, and Talented Education while Elijah has been battling brain cancer.

Newswise:  Montefiore Einstein Comprehensive Cancer Center Establishes New Immunotherapy Institute
Released: 16-Sep-2024 9:05 AM EDT
Montefiore Einstein Comprehensive Cancer Center Establishes New Immunotherapy Institute
Montefiore Einstein Comprehensive Cancer Center

The National Cancer Institute-designated Montefiore Einstein Comprehensive Cancer Center (MECCC) has announced the new Marilyn and Stanley M. Katz Institute for Immunotherapy for Cancer and Inflammatory Disorders. Xingxing Zang, Ph.D., an international leader in developing novel immunotherapies, has been named its inaugural director.

access_time Embargo lifts in 2 days
Embargo will expire: 17-Sep-2024 11:00 AM EDT Released to reporters: 16-Sep-2024 8:05 AM EDT

A reporter's PressPass is required to access this story until the embargo expires on 17-Sep-2024 11:00 AM EDT The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Newswise: sabygeorgenewweb.jpg
Released: 15-Sep-2024 11:05 AM EDT
Roswell Park-Designed Treatment Regimen Doubles Progression-Free Survival in Metastatic Kidney Cancer
Roswell Park Comprehensive Cancer Center

During the European Society for Medical Oncology (ESMO) Congress, Saby George, MD, FACP, of Roswell Park Comprehensive Cancer Center presented findings on a novel two-agent treatment that more than doubled progression-free survival compared with single-agent treatment.

13-Sep-2024 9:45 AM EDT
ESMO: Combination Therapy Reduced Agitated Delirium in Patients with Advanced Cancers
University of Texas MD Anderson Cancer Center

Treatment with a combination of haloperidol and lorazepam reduced symptoms of agitated delirium, a common end-of-life condition for patients with advanced cancers, compared with haloperidol alone, according to a new study led by researchers at The University of Texas MD Anderson Cancer Center.

Newswise: Scientist Awarded National Institutes of Health Grant to Examine Cancer-Dependent Enzyme
Released: 13-Sep-2024 12:05 PM EDT
Scientist Awarded National Institutes of Health Grant to Examine Cancer-Dependent Enzyme
Virginia Tech

During every moment of any living organism’s life, enzymes are at work. These crucial proteins support life through most biological processes, including metabolism, movement, respiration, and digestion. “Enzymes’ effects in cells are part of normal physiology,” said Kathleen Mulvaney, assistant professor at Virginia Tech’s Fralin Biomedical Research Institute.

Newswise: Antibody-Drug Conjugate Found Effective Against Brain Metastases in Patients with HER2-Positive Breast Cancer
Released: 13-Sep-2024 11:05 AM EDT
Antibody-Drug Conjugate Found Effective Against Brain Metastases in Patients with HER2-Positive Breast Cancer
Dana-Farber Cancer Institute

A drug that delivers chemotherapy directly to tumors has shown impressive activity against some of the hardest-to-reach cancer cells: those that have spread to the brain in patients with advanced HER2-positive breast cancer. Research led by Dana-Farber Cancer Institute.

access_time Embargo lifts in 2 days
Embargo will expire: 18-Sep-2024 5:00 PM EDT Released to reporters: 13-Sep-2024 10:05 AM EDT

A reporter's PressPass is required to access this story until the embargo expires on 18-Sep-2024 5:00 PM EDT The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Newswise: Repeat Immune Checkpoint Inhibitor Therapy Not Recommended for Advanced Kidney Cancer
Released: 13-Sep-2024 10:05 AM EDT
Repeat Immune Checkpoint Inhibitor Therapy Not Recommended for Advanced Kidney Cancer
Dana-Farber Cancer Institute

In an international multicenter randomized phase 3 clinical trial led by Dana-Farber Cancer Institute, researchers tested the addition of the immune checkpoint inhibitor (ICI) nivolumab to treatment with tivozanib for patients with advanced clear cell renal cell carcinoma.

Newswise: funda_meric-bernstam.jpg.resize.405.575.high.jpg
Released: 13-Sep-2024 9:05 AM EDT
ESMO: Novel ADC AZD8205 Demonstrates Manageable Safety Profile and Preliminary Efficacy in First-in-Human Trial
University of Texas MD Anderson Cancer Center

The antibody-drug conjugate (ADC) puxitatug samrotecan (AZD8205) demonstrated a manageable safety profile consistent with similar ADCs and initial efficacy in heavily pretreated patients with advanced or metastatic solid tumors, according to interim data shared today at the 2024 European Society for Medical Oncology (ESMO) Congress by researchers from The University of Texas MD Anderson Cancer Center.

Newswise: Celebrating 25 Years of Innovative Cancer Research and World-class Cancer Care
Released: 12-Sep-2024 5:05 PM EDT
Celebrating 25 Years of Innovative Cancer Research and World-class Cancer Care
Huntsman Cancer Institute at the University of Utah

Explore how Huntsman Cancer Institute's 25-year legacy of excellence is reaching new heights and advancing cancer treatments of the future beyond the standard of care today.

Newswise: Overcoming Drug Resistance in Breast Cancer Treatment
Released: 12-Sep-2024 5:05 PM EDT
Overcoming Drug Resistance in Breast Cancer Treatment
College of Liberal Arts and Sciences, University of Illinois Urbana-Champaign

An interdisciplinary team of researchers from the University of Illinois has discovered a potential new treatment option for drug-resistant breast cancer. Their findings, published in Breast Cancer Research and Treatment, demonstrates the role of activators of ferroptosis in overcoming acquired resistance to FOXM1 inhibitors.

Newswise: csm_20240903_parasites-genetiques-couverture_a66a283cf9.jpg
Released: 12-Sep-2024 4:05 PM EDT
Do Genetic "Parasites" Help the Immune System Develop and Function?
Universite de Montreal

A study by UdeM professor Claude Perreault's team at IRIC proposes three potential functions for so-called parasite DNA sequences in T cell development.

Newswise: 1920_biomanufacturing-center-cedars-sinai.jpg?10000
Released: 12-Sep-2024 10:05 AM EDT
New Resource for California Stem Cell Scientists
Cedars-Sinai

The Cedars-Sinai Board of Governors Regenerative Medicine Institute is creating a resource laboratory to help advance stem cell-based technologies throughout Cedars-Sinai and across California.

Released: 12-Sep-2024 10:05 AM EDT
Using a Molecular Scissors to Improve CAR-T Cell Therapy
Mayo Clinic

Mayo Clinic researchers mined the molecular foundations of cancer and uncovered a new reason chimeric antigen receptor (CAR-T cell therapy) fails in some patients. This discovery has fueled new strategies that incorporate antibodies and gene editing to improve the outcome of this breakthrough treatment for patients.


  • Previous Page
  • Next Page

Showing results

11 of 1

close
4.57959